Atopic dermatitis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 12: Line 12:


==Differentiating [Disease name] from other Diseases==
==Differentiating [Disease name] from other Diseases==
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
* '''Chronic inflammatory skin diseases'''
** Contact (allergic, irritant)
** Seborrhoeic dermatitis  
** Seborrhoeic dermatitis  
*** onset during the 1st days or weeks of life, absence of pruritus, and presence of greasy scaling on a yellow-red base
*** onset during the 1st days or weeks of life, absence of pruritus, and presence of greasy scaling on a yellow-red base
*** Involvement of the top of the scalp (cradle cap), axilla, and diaper area makes it more likely the patient has '''seborrheic dermatitis''', vs excoriated dermatitis involving the extensor surfaces, face, and trunk favour '''AE.'''
*** Involvement of the top of the scalp (cradle cap), axilla, and diaper area makes it more likely the patient has '''seborrheic dermatitis''', vs excoriated dermatitis involving the extensor surfaces, face, and trunk favour '''AE.'''
** Psoriasis
** Lichen simplex chronicus
* '''Infectious agents'''
** Candida
** Dermatophytes
** Herpes simplex
** Staphylococcus aureus
** Sarcoptes scabiei  
** Sarcoptes scabiei  
*** highly pruritic, erythematous papular lesions. In most cases, the typical burrows can be found on the flexor wrists, finger webs and genitalia. Similar symptoms in other family members
*** highly pruritic, erythematous papular lesions. In most cases, the typical burrows can be found on the flexor wrists, finger webs and genitalia. Similar symptoms in other family members
** HIV-associated dermatitis
* '''Immunologic disorders'''
** Dermatitis herpetiformis
** Pemphigus foliaceus
** Graft-versus-host disease
** Dermatomyositis
* '''Malignant Diseases'''
** Cutaneous T-cell lymphoma (mycosis fungoides, S´ezary syndrome)
** Histiocytosis X (Letterer-Siwe disease)
* '''Congenital disorders'''
** Netherton’s syndrome
** Dubowitz syndrome
** Erythrokeratodermia variabilis
* '''Immunodeficiencies'''
** Wiskott-Aldrich syndrome (immunodeficiency with thrombocytopenia and eczema)
** Thymic hypoplasia (DiGeorge syndrome)
** Hyper-IgE syndrome
** Severe combined immunodeficiency (SCID)
** Ataxia telangiectasia
* '''Metabolic Diseases'''
** Phenylketonuria
** Tyrosinemia
** Histidinemia
** Zinc deficiency
** Pyridoxine (vitamin B6) and niacin deficiency
** Multiple carboxylase deficiency
* '''Nonallergic reaction to medication'''
** Infliximab
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
!
! rowspan="5" |Category
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
|Etiology
| rowspan="5" |Etiology
|Congenital
| rowspan="5" |Inherited
|Acquired
| rowspan="5" |Acquired
|Demography
| rowspan="5" |Demography
|History
| rowspan="5" |History
| colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="11" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
|
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
|
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|
|
|
|
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
!
! colspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
!
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
!
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
!
!
!
! colspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-
|-
!
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
!
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Itching
!
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
!
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
!
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
!
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
!Nail pitting
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Itching
! rowspan="2" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
!Other
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BUN/Cr
! rowspan="2" |Electrolytes
!LFT
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BUN/Cr
! rowspan="2" |LFT
|-
|-
!
!Single/
!
Multiple
!
!Rash
!
!Involved areas
!
!Pustule
!
!
!
!
!
!
!
!
!
!
!WBC
!WBC
!Hb
!Hb
!Plt
!Plt
!
!
!
!
!
!
!
|-
|-
| rowspan="10" |Skin disorders
| rowspan="10" |Skin disorders
Line 139: Line 70:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 144: Line 78:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 149: Line 84:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 163: Line 99:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 168: Line 107:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 173: Line 113:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 187: Line 128:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 192: Line 136:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 197: Line 142:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 211: Line 157:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 216: Line 165:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 221: Line 171:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 229: Line 180:
|-
|-
|Lichen simplex chronicus
|Lichen simplex chronicus
|
|
|
|
|
|
|
|
|
Line 253: Line 209:
|-
|-
|'''Ichthyosis vulgaris'''
|'''Ichthyosis vulgaris'''
|
|
|
|
|
|
|
|
|
Line 277: Line 238:
|-
|-
|'''Nummular Dermatitis'''
|'''Nummular Dermatitis'''
|
|
|
|
|
|
|
|
|
Line 301: Line 267:
|-
|-
|Netherton syndrome
|Netherton syndrome
|
|
|
|
|
|
|
|
|
Line 325: Line 296:
|-
|-
|Dubowitz syndrome
|Dubowitz syndrome
|
|
|
|
|
|
|
|
|
Line 349: Line 325:
|-
|-
|Erythrokeratodermia variabilis
|Erythrokeratodermia variabilis
|
|
|
|
|
|
|
|
|
Line 372: Line 353:
|
|
|-
|-
| rowspan="6" |Infection
| rowspan="7" |Infection
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Dermatophytes
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Dermatophytes
|
|
Line 380: Line 361:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 385: Line 369:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 390: Line 375:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 398: Line 384:
|-
|-
|Candida
|Candida
|
|
|
|
|
|
|
|
|
Line 422: Line 413:
|-
|-
|Herpes simplex
|Herpes simplex
|
|
|
|
|
|
|
|
|
Line 446: Line 442:
|-
|-
|Staphylococcus aureus
|Staphylococcus aureus
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Molluscum Contagiosum
|
|
|
|
|
|
|
|
|
Line 470: Line 500:
|-
|-
|'''Scabies'''
|'''Scabies'''
|
|
|
|
|
|
|
|
|
Line 494: Line 529:
|-
|-
|HIV
|HIV
|
|
|
|
|
|
|
|
|
Line 519: Line 559:
| rowspan="4" |Immunologic disorders
| rowspan="4" |Immunologic disorders
|Dermatitis herpetiformis
|Dermatitis herpetiformis
|
|
|
|
|
|
|
|
|
Line 543: Line 588:
|-
|-
|Pemphigus foliaceus
|Pemphigus foliaceus
|
|
|
|
|
|
|
|
|
Line 567: Line 617:
|-
|-
|Graft-versus-host disease
|Graft-versus-host disease
|
|
|
|
|
|
|
|
|
Line 591: Line 646:
|-
|-
|Dermatomyositis
|Dermatomyositis
|
|
|
|
|
|
|
|
|
Line 622: Line 682:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 627: Line 690:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 632: Line 696:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 646: Line 711:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 651: Line 719:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 656: Line 725:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 664: Line 734:
|-
|-
|DiGeorge syndrome
|DiGeorge syndrome
|
|
|
|
|
|
|
|
|
Line 688: Line 763:
|-
|-
|Severe combined immunodeficiency (SCID)
|Severe combined immunodeficiency (SCID)
|
|
|
|
|
|
|
|
|
Line 712: Line 792:
|-
|-
|Ataxia telangiectasia
|Ataxia telangiectasia
|
|
|
|
|
|
|
|
|
Line 737: Line 822:
| rowspan="4" |'''Metabolic Diseases'''
| rowspan="4" |'''Metabolic Diseases'''
|Phenylketonuria
|Phenylketonuria
|
|
|
|
|
|
|
|
|
Line 761: Line 851:
|-
|-
|Tyrosinemia
|Tyrosinemia
|
|
|
|
|
|
|
|
|
Line 785: Line 880:
|-
|-
|Histidinemia
|Histidinemia
|
|
|
|
|
|
|
|
|
Line 809: Line 909:
|-
|-
|Multiple carboxylase deficiency
|Multiple carboxylase deficiency
|
|
|
|
|
|
|
|
|
Line 840: Line 945:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 845: Line 953:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 850: Line 959:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 857: Line 967:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
|Pyridoxine deficiency
|Niacin (B3) deficiency
|
|
|
|
|
|
|
|
|
Line 881: Line 996:
|
|
|-
|-
|Niacin deficiency
|Pyridoxine (B6) deficiency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|
|Biotin (B7) deficiency
|
|
|
|
|
|
|
|
|
Line 913: Line 1,063:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 918: Line 1,071:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 923: Line 1,077:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
Line 931: Line 1,086:
|-
|-
|Histiocytosis X
|Histiocytosis X
|
|
|
|
|
|
|
|
|
Line 956: Line 1,116:
|Medications
|Medications
|Infliximab
|Infliximab
|
|
|
|
|
|
|
|
|

Revision as of 16:12, 11 October 2018

Atopic dermatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atopic dermatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atopic dermatitis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atopic dermatitis differential diagnosis

CDC on Atopic dermatitis differential diagnosis

Atopic dermatitis differential diagnosis in the news

Blogs onAtopic dermatitis differential diagnosis

Directions to Hospitals Treating Atopic dermatitis

Risk calculators and risk factors forAtopic dermatitis differential diagnosis

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.


Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atopic dermatitis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atopic dermatitis differential diagnosis

CDC on Atopic dermatitis differential diagnosis

Atopic dermatitis differential diagnosis in the news

Blogs on Atopic dermatitis differential diagnosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Atopic dermatitis differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

Differentiating [Disease name] from other Diseases

    • Seborrhoeic dermatitis
      • onset during the 1st days or weeks of life, absence of pruritus, and presence of greasy scaling on a yellow-red base
      • Involvement of the top of the scalp (cradle cap), axilla, and diaper area makes it more likely the patient has seborrheic dermatitis, vs excoriated dermatitis involving the extensor surfaces, face, and trunk favour AE.
    • Sarcoptes scabiei
      • highly pruritic, erythematous papular lesions. In most cases, the typical burrows can be found on the flexor wrists, finger webs and genitalia. Similar symptoms in other family members
Category Diseases Etiology Inherited Acquired Demography History Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Appearance Itching Bleeding Fever BP Tenderness Nail pitting Other CBC ESR/CRP Electrolytes BUN/Cr LFT
Single/

Multiple

Rash Involved areas Pustule WBC Hb Plt
Skin disorders Allergic contact dermatitis
Irritant contact dermatitis
Seborrheic dermatitis
Psoriasis
Lichen simplex chronicus
Ichthyosis vulgaris
Nummular Dermatitis
Netherton syndrome
Dubowitz syndrome
Erythrokeratodermia variabilis
Infection Dermatophytes
Candida
Herpes simplex
Staphylococcus aureus
Molluscum Contagiosum
Scabies
HIV
Immunologic disorders Dermatitis herpetiformis
Pemphigus foliaceus
Graft-versus-host disease
Dermatomyositis
Immune deficiency Wiskott-Aldrich syndrome
Hyper-IgE syndrome
DiGeorge syndrome
Severe combined immunodeficiency (SCID)
Ataxia telangiectasia
Metabolic Diseases Phenylketonuria
Tyrosinemia
Histidinemia
Multiple carboxylase deficiency
Nutritional deficiencies Zinc deficiency
Niacin (B3) deficiency
Pyridoxine (B6) deficiency
Biotin (B7) deficiency
Malignancy Mycosis fungoides
Histiocytosis X
Medications Infliximab

References


Template:WikiDoc Sources